Guest guest Posted November 26, 2005 Report Share Posted November 26, 2005 Hi All, Jan Still wrote: > Hello Clarissa and all, Could you please let us see any literature data > which would actually bring an EVIDENCE that the L-Lysine > supplementation leads to a reduction of the incidence (or duration) of > the herpes infection & its symptoms? Any data in man or animals > (including a control/placebo group) would be good. Thanks Jan A Medline search for the profile (lysine AND herpes) is at: http://tinyurl.com/cgob6 There are 125 references but opinions on the efficacy of L-Lysine are divided. For example, see: FOR an effect of lysine in herpes: Altern Med Rev. 2005 Jun;10(2):123-7. Safety and effectiveness of an L-lysine, zinc, and herbal-based product on the treatment of facial and circumoral herpes. Singh BB, Udani J, Vinjamury SP, Der-Martirosian C, Gandhi S, Khorsan R, Nanjegowda D, Singh V. Southern California University of Health Sciences, SCU Research Division, 16200 E. Amber Valley Drive, Whittier, California 90604, USA. drbetsysingh CONTEXT: L-lysine, an essential amino acid, inhibits normal replication of Herpes simplex virus (HSV), shortening the normal course and duration of the disease. This study was conducted to determine the effectiveness of a combination of L-lysine with botanicals and other nutrients in relieving the symptoms of facial and circumoral herpes. METHODS: This small pilot study was conducted using an outcome (open-label) model. Thirty male and female participants (15 in each group) meeting the inclusion/exclusion criteria were admitted to the study. The 10 outcome measures used to monitor the sores were tingling, itching, burning, tenderness, prickling, soreness, bump/swelling, small blister(s), oozing blister(s), and crusting, as well as before-and- after photographs of the lesion, and a daily diary. RESULTS: At the end of treatment the ointment produced full resolution in 40 percent of the participants by the third day and in 87 percent by the end of the sixth day. A cold sore episode may last up to 21 days without treatment. CONCLUSIONS: Overall data indicated significant improvement in participants by the sixth day of treatment for all but two participants. There were no adverse effects reported during this study. PMID: 15989381 [PubMed - indexed for MEDLINE] Am Fam Physician. 2005 Oct 15;72(8):1527-34. Genital herpes: a review. Beauman JG. Evans U.S. Army Hospital, Fort Carson, Colorado 80913, USA. Genital herpes simplex virus infection is a recurrent, lifelong disease with no cure. The strongest predictor for infection is a person's number of lifetime sex partners. The natural history includes first-episode mucocutaneous infection, establishment of latency in the dorsal root ganglion, and subsequent reactivation. Most infections are transmitted via asymptomatic viral shedding. Classic outbreaks consist of a skin prodrome and possible constitutional symptoms such as headache, fever, and inguinal lymphadenopathy. As the infection progresses, papules, vesicles on an erythematous base, and erosions appear over hours to days. These lesions usually crust, re- epithelialize, and heal without scarring. First-episode infections are more extensive: primary lesions last two to six weeks versus approximately one week for lesions in recurrent disease. Atypical manifestations are common. Infected persons experience a median of four recurrences per year after their first episode, but rates vary greatly. Genital herpes simplex virus type 2 recurs six times more frequently than type 1. Viral culture is preferred over polymerase chain reaction testing for diagnosis. Serologic testing can be useful in persons with a questionable history. Effective oral antiviral medications are available for initial, episodic, and suppressive therapy but are not a cure. There is some evidence that alternative therapies such as L-lysine, zinc, and some herbal preparations may offer some benefit. Counseling patients about the risk of transmission is crucial and helps prevent the spread of disease and neonatal complications. PMID: 16273819 [PubMed - in process] Dermatologica. 1987;175(4):183-90. Success of L-lysine therapy in frequently recurrent herpes simplex infection. Treatment and prophylaxis. Griffith RS, Walsh DE, Myrmel KH, Thompson RW, Behforooz A. Department of Medicine, Indiana University School of Medicine, Indianapolis. A double-blind, placebo-controlled, multicenter trial of oral L-lysine monohydrochloride for the prevention and treatment of recurrent herpes simplex (HSV) infection was conducted. The treatment group was given L-Lysine monohydrochloride tablets (1,000 mg L-lysine per dose) tid for 6 months. A total of 27 (6 male and 21 female) subjects on L-lysine and 25 (6 male and 19 female) subjects on placebo completed the trial. The L-lysine treatment group had an average of 2.4 (p less than 0.05) less HSV infections, symptoms were significantly (p less than 0.05) diminished in severity and healing time was significantly reduced (p less than 0.05). L-Lysine appears to be an effective agent for reduction of occurrence, severity and healing time for recurrent HSV infection. Publication Types: Clinical Trial Controlled Clinical Trial PMID: 3115841 [PubMed - indexed for MEDLINE] AGAINST an effect of lysine in herpes: Herpes. 2005 Oct;12(2):38-41. Use of complementary and alternative medicine for the treatment of genital herpes. Perfect MM, Bourne N, Ebel C, Rosenthal SL. Department of Pediatrics and Sealy Center for Vaccine Development, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555, USA. Conventional antiviral drugs have proven effectiveness for genital herpes; however, patients continue to use a variety of complementary and alternative medicine (CAM) treatments. Given that patients may be using these products, it is important that healthcare providers become familiar with the data regarding safety and efficacy. We have reviewed available scientific data on six commonly used treatments (echinacea, eleuthero, L-lysine, zinc, bee products and aloe). Also, information about a number of other products is presented in tabular form. Currently, there are insufficient clinical data to be confident of the efficacy and safety of any of these products for the treatment of genital herpes. It is hoped that future clinical trials will be conducted with sufficient rigour to provide guidance to the patients using these products. PMID: 16209859 [PubMed - in process] I have not time to review the 125 abstracts. Any volunteers to do so and post a summary to the List? Best regards, Tel: (H): +353-(0) or (M): +353-(0) Ireland. Tel: (W): +353-(0) or (M): +353-(0) " Man who says it can't be done should not interrupt man doing it " - Chinese Proverb Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 27, 2005 Report Share Posted November 27, 2005 Hi All, Jan Still wrote: > Hello Clarissa and all, Could you please let us see any literature data > which would actually bring an EVIDENCE that the L-Lysine > supplementation leads to a reduction of the incidence (or duration) of > the herpes infection & its symptoms? Any data in man or animals > (including a control/placebo group) would be good. Thanks Jan A Medline search for the profile (lysine AND herpes) is at: http://tinyurl.com/cgob6 There are 125 references but opinions on the efficacy of L-Lysine are divided. For example, see: FOR an effect of lysine in herpes: Altern Med Rev. 2005 Jun;10(2):123-7. Safety and effectiveness of an L-lysine, zinc, and herbal-based product on the treatment of facial and circumoral herpes. Singh BB, Udani J, Vinjamury SP, Der-Martirosian C, Gandhi S, Khorsan R, Nanjegowda D, Singh V. Southern California University of Health Sciences, SCU Research Division, 16200 E. Amber Valley Drive, Whittier, California 90604, USA. drbetsysingh CONTEXT: L-lysine, an essential amino acid, inhibits normal replication of Herpes simplex virus (HSV), shortening the normal course and duration of the disease. This study was conducted to determine the effectiveness of a combination of L-lysine with botanicals and other nutrients in relieving the symptoms of facial and circumoral herpes. METHODS: This small pilot study was conducted using an outcome (open-label) model. Thirty male and female participants (15 in each group) meeting the inclusion/exclusion criteria were admitted to the study. The 10 outcome measures used to monitor the sores were tingling, itching, burning, tenderness, prickling, soreness, bump/swelling, small blister(s), oozing blister(s), and crusting, as well as before-and- after photographs of the lesion, and a daily diary. RESULTS: At the end of treatment the ointment produced full resolution in 40 percent of the participants by the third day and in 87 percent by the end of the sixth day. A cold sore episode may last up to 21 days without treatment. CONCLUSIONS: Overall data indicated significant improvement in participants by the sixth day of treatment for all but two participants. There were no adverse effects reported during this study. PMID: 15989381 [PubMed - indexed for MEDLINE] Am Fam Physician. 2005 Oct 15;72(8):1527-34. Genital herpes: a review. Beauman JG. Evans U.S. Army Hospital, Fort Carson, Colorado 80913, USA. Genital herpes simplex virus infection is a recurrent, lifelong disease with no cure. The strongest predictor for infection is a person's number of lifetime sex partners. The natural history includes first-episode mucocutaneous infection, establishment of latency in the dorsal root ganglion, and subsequent reactivation. Most infections are transmitted via asymptomatic viral shedding. Classic outbreaks consist of a skin prodrome and possible constitutional symptoms such as headache, fever, and inguinal lymphadenopathy. As the infection progresses, papules, vesicles on an erythematous base, and erosions appear over hours to days. These lesions usually crust, re- epithelialize, and heal without scarring. First-episode infections are more extensive: primary lesions last two to six weeks versus approximately one week for lesions in recurrent disease. Atypical manifestations are common. Infected persons experience a median of four recurrences per year after their first episode, but rates vary greatly. Genital herpes simplex virus type 2 recurs six times more frequently than type 1. Viral culture is preferred over polymerase chain reaction testing for diagnosis. Serologic testing can be useful in persons with a questionable history. Effective oral antiviral medications are available for initial, episodic, and suppressive therapy but are not a cure. There is some evidence that alternative therapies such as L-lysine, zinc, and some herbal preparations may offer some benefit. Counseling patients about the risk of transmission is crucial and helps prevent the spread of disease and neonatal complications. PMID: 16273819 [PubMed - in process] Dermatologica. 1987;175(4):183-90. Success of L-lysine therapy in frequently recurrent herpes simplex infection. Treatment and prophylaxis. Griffith RS, Walsh DE, Myrmel KH, Thompson RW, Behforooz A. Department of Medicine, Indiana University School of Medicine, Indianapolis. A double-blind, placebo-controlled, multicenter trial of oral L-lysine monohydrochloride for the prevention and treatment of recurrent herpes simplex (HSV) infection was conducted. The treatment group was given L-Lysine monohydrochloride tablets (1,000 mg L-lysine per dose) tid for 6 months. A total of 27 (6 male and 21 female) subjects on L-lysine and 25 (6 male and 19 female) subjects on placebo completed the trial. The L-lysine treatment group had an average of 2.4 (p less than 0.05) less HSV infections, symptoms were significantly (p less than 0.05) diminished in severity and healing time was significantly reduced (p less than 0.05). L-Lysine appears to be an effective agent for reduction of occurrence, severity and healing time for recurrent HSV infection. Publication Types: Clinical Trial Controlled Clinical Trial PMID: 3115841 [PubMed - indexed for MEDLINE] AGAINST an effect of lysine in herpes: Herpes. 2005 Oct;12(2):38-41. Use of complementary and alternative medicine for the treatment of genital herpes. Perfect MM, Bourne N, Ebel C, Rosenthal SL. Department of Pediatrics and Sealy Center for Vaccine Development, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555, USA. Conventional antiviral drugs have proven effectiveness for genital herpes; however, patients continue to use a variety of complementary and alternative medicine (CAM) treatments. Given that patients may be using these products, it is important that healthcare providers become familiar with the data regarding safety and efficacy. We have reviewed available scientific data on six commonly used treatments (echinacea, eleuthero, L-lysine, zinc, bee products and aloe). Also, information about a number of other products is presented in tabular form. Currently, there are insufficient clinical data to be confident of the efficacy and safety of any of these products for the treatment of genital herpes. It is hoped that future clinical trials will be conducted with sufficient rigour to provide guidance to the patients using these products. PMID: 16209859 [PubMed - in process] I have not time to review the 125 abstracts. Any volunteers to do so and post a summary to the List? Best regards, Tel: (H): +353-(0) or (M): +353-(0) Ireland. Tel: (W): +353-(0) or (M): +353-(0) " Man who says it can't be done should not interrupt man doing it " - Chinese Proverb Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.